References
- Hayward AC, Fragaszy EB, Bermingham A, et al. Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. Lancet Respir Med 2014;2(6):445-54
- Claas EC, Osterhaus AD, van Beek R, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998;351(9101):472-7
- Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013;368(20):1888-97
- Chen H, Yuan H, Gao R, et al. Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. Lancet 2014;383(9918):714-21
- Koel BF, Burke DF, Bestebroer TM, et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 2013;342(6161):0976-9
- Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009;8(4):499-508
- El Bakkouri K, Descamps F, De Filette M, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 2011;186(2):1022-31
- Krammer F, Palese P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 2013;3(5):521-30
- Krammer F, Palese P, Steel J. Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Curr Top Microbiol Immunol 2015;386:301-21
- Marcelin G, DuBois R, Rubrum A, et al. A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1. 2009 influenza A virus. PLoS One 2011;6(10):e26335
- Wohlbold TJ, Nachbagauer R, Xu H, et al. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. mBio 2015;6(2):e02556
- van de Sandt CE, Kreijtz JH, Rimmelzwaan GF. Evasion of influenza A viruses from innate and adaptive immune responses. Viruses 2012;4(9):1438-76
- Altenburg AF, Rimmelzwaan GF, de Vries RD. Virus-specific T cells as correlate of (cross-)protective immunity against influenza. Vaccine 2015;33(4):500-6
- Hillaire ML, Vogelzang-van Trierum SE, Kreijtz JH, et al. Human T-cells directed to seasonal influenza A virus cross-react with. 2009 pandemic influenza A (H1N1) and swine-origin triple-reassortant H3N2 influenza viruses.The Journal of general virology 2013;94(Pt 3):583-92
- Kreijtz JH, de Mutsert G, van Baalen CA, et al. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 2008;82(11):5161-6
- van de Sandt CE, Kreijtz JH, de Mutsert G, et al. Human cytotoxic T lymphocytes directed to seasonal influenza a viruses cross-react with the newly emerging H7N9 virus. J Virol 2014;88(3):1684-93
- Sridhar S, Begom S, Bermingham A, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 2013;19(10):1305-12
- Altenburg AF, Kreijtz JH, de Vries RD, et al. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 2014;6(7):2735-61
- Kreijtz JH, Goeijenbier M, Moesker FM, et al. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. Lancet Infect Dis 2014;14(12):1196-207
- Berthoud TK, Hamill M, Lillie PJ, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 2011;52(1):1-7